Affimed N.V. (NASDAQ:AFMD)’s quarterly earnings will be published on March, 19., according to Zacks. Last year’s EPS was $-0.16, while now analysts expect change of 6.25 % down from current $-0.17 EPS. After $-0.22 EPS report last quarter, Wall Street now forecasts -22.73 % EPS growth of Affimed N.V.. AFMD reached $3.81 during the last trading session after $0.3 change.Affimed N.V. has 1.11 million shares volume, 108.19% up from normal. AFMD is uptrending and has moved 88.42% since March 2, 2018. AFMD outperformed by 88.42% the S&P 500.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally.The company has $237.85 million market cap. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.Currently it has negative earnings. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

For more Affimed N.V. (NASDAQ:AFMD) news published recently go to: Seekingalpha.com, Benzinga.com, Globenewswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “A Company In Decline? The Case For/Against Affimed After Bad News – Seeking Alpha” published on October 14, 2018, “Affimed (NASDAQ:AFMD) Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data – Benzinga” on June 15, 2018, “Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day – GlobeNewswire” with a publish date: December 07, 2018, “Affimed Clinical Hold Likely To Be Resolved Soon – Seeking Alpha” and the last “Affimed: Positive Takeaways From AFM-13 Focused R&D Day; Multiple Catalysts Ahead Including Potential Partnership With PD1/PD-L1 Company For AFM13 Combo Trial – Seeking Alpha” with publication date: December 12, 2018.